Personalis, Inc. (PSNL) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Personalis, Inc. (PSNL) trades at $13.34 with AI Score 21/100 (Grade F). Personalis, Inc. is a cancer genomics company providing sequencing and data analysis services. Market cap: $1.18B, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: May 10, 2026PSNL stock analysis for 2026: Analysts have set a consensus price target of $13.00 for Personalis, Inc., suggesting 2.5% downside from the current price of $13.34. The AI MoonshotScore is 21/100, indicating a strong bearish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
PSNL: 3/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Personalis, Inc. (PSNL) Healthcare & Pipeline Overview
Personalis, Inc. is a cancer genomics company offering advanced sequencing and data analysis solutions, including the NeXT Platform, to biopharmaceutical companies, universities, and research institutions. The company focuses on enabling the development of personalized cancer therapies and advancing large-scale genetic research programs within the competitive healthcare diagnostics market.
What Is the Investment Thesis for PSNL?
Personalis, Inc. presents a compelling investment thesis centered on its innovative cancer genomics platform and strategic partnerships. The company's NeXT platform and related services cater to the growing demand for personalized cancer therapies and advanced genetic research. With a market capitalization of $1.18B, Personalis operates in a high-growth sector driven by increasing investments in cancer research and precision medicine. Key value drivers include the expansion of its NeXT platform capabilities, strategic collaborations with biopharmaceutical companies and research institutions, and the potential for increased adoption of its liquid biopsy solutions. However, the company's negative profit margin of -148.1% and a high beta of 2.21 indicate significant financial risks and market volatility. Successful execution of its growth strategies and improved financial performance are crucial for realizing its long-term potential.
Based on FMP financials and quantitative analysis
PSNL Key Highlights
- Market Cap of $1.18B reflects investor valuation of Personalis' potential in the cancer genomics market.
- Gross Margin of 13.7% indicates the profitability of Personalis' core services after accounting for direct costs.
- Profit Margin of -148.1% highlights the company's current challenges in achieving profitability despite revenue generation.
- Beta of 2.21 suggests higher volatility compared to the overall market, indicating potential for significant price fluctuations.
- Partnerships with Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center demonstrate strategic collaborations to expand research and market reach.
Who Are PSNL's Competitors?
PSNL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EXAS Exact Sciences Corporation | $104.91 | +0.00% | $20.0B | 62 |
| GH Guardant Health, Inc. | $155.87 | +0.56% | $20.7B | 34 |
| OLK Olink Holding AB (publ) | $26.08 | +0.31% | $3.24B | 58 |
| DSRLF DiaSorin S.p.A. | $77.58 | -3.51% | $3.84B | 52 |
| PRE Prenetics Global Limited | $20.02 | +9.45% | $340M | 69 |
| EDTXF Spectral Medical Inc. | $1.00 | -0.99% | $293M | 56 |
| SHC Sotera Health Company | $17.42 | -1.86% | $4.97B | 78 |
| OPGN OpGen, Inc. | $23.91 | +64.36% | $243M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PSNL's Key Strengths?
- Advanced NeXT Platform for comprehensive genomic analysis.
- Strategic partnerships with leading research institutions.
- Diverse product portfolio for tumor profiling and personalized treatment.
- Expertise in sequencing and data analysis.
What Are PSNL's Weaknesses?
- Negative profit margin indicating financial challenges.
- High beta suggesting market volatility.
- Reliance on partnerships for research and development.
- Limited geographic presence.
What Could Drive PSNL Stock Higher?
- Expansion of NeXT Platform capabilities with AI and machine learning in Q3 2026.
- Announcement of new strategic partnerships with biopharmaceutical companies in Q4 2026.
- Increased adoption of liquid biopsy solutions for early cancer detection.
- Geographic expansion into emerging markets in Asia-Pacific.
What Are the Key Risks for PSNL?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Intense competition from established diagnostic companies like Exact Sciences and Guardant Health.
- Regulatory hurdles and reimbursement challenges affecting market access.
- Technological advancements by competitors leading to loss of market share.
- Economic downturn affecting research funding and customer spending.
- Negative profit margin indicating financial instability.
What Are the Growth Opportunities for PSNL?
- Expansion of NeXT Platform Capabilities: Personalis can enhance its NeXT platform by incorporating advanced data analytics and machine learning algorithms to improve the accuracy and efficiency of tumor profiling. The global market for AI in drug discovery is projected to reach $4.0 billion by 2027, presenting a significant opportunity for Personalis to integrate AI-driven solutions into its platform. This expansion can attract more biopharmaceutical clients seeking comprehensive genomic insights for drug development, with an estimated timeline of 1-2 years for implementation.
- Strategic Partnerships with Biopharmaceutical Companies: Personalis can forge deeper collaborations with biopharmaceutical companies to co-develop personalized cancer therapies and companion diagnostics. The market for companion diagnostics is expected to reach $7.8 billion by 2028. By partnering with leading pharmaceutical firms, Personalis can secure long-term contracts and revenue streams, while also gaining access to valuable clinical data and market expertise. These partnerships can be established within the next 12-18 months.
- Increased Adoption of Liquid Biopsy Solutions: Personalis can drive the adoption of its NeXT Liquid Biopsy for personalized tumor tracking by demonstrating its clinical utility and cost-effectiveness. The global liquid biopsy market is projected to reach $6.6 billion by 2025. By showcasing the benefits of its liquid biopsy solutions in early cancer detection and treatment monitoring, Personalis can expand its market share and generate recurring revenue from patient monitoring programs. This expansion can occur over the next 2-3 years.
- Geographic Expansion into Emerging Markets: Personalis can expand its geographic footprint by entering emerging markets with high unmet needs for cancer diagnostics and treatment. The Asia-Pacific region is expected to be the fastest-growing market for cancer diagnostics, driven by increasing healthcare expenditure and a rising prevalence of cancer. By establishing partnerships with local hospitals and research institutions, Personalis can gain access to new patient populations and revenue streams within the next 3-5 years.
- Development of Novel Biomarkers and Drug Targets: Personalis can leverage its ACE platform to identify novel biomarkers and drug targets for cancer therapy. The market for biomarker discovery is projected to reach $6.2 billion by 2027. By developing innovative biomarkers and drug targets, Personalis can attract research funding and licensing agreements, while also contributing to the advancement of cancer treatment. This development can be achieved through ongoing research and development efforts over the next 3-5 years.
What Opportunities Does PSNL Have?
- Expansion of NeXT Platform capabilities with AI and machine learning.
- Increased adoption of liquid biopsy solutions for early detection.
- Geographic expansion into emerging markets.
- Development of novel biomarkers and drug targets.
What Threats Does PSNL Face?
- Intense competition from established diagnostic companies.
- Regulatory hurdles and reimbursement challenges.
- Technological advancements by competitors.
- Economic downturn affecting research funding.
What Are PSNL's Competitive Advantages?
- Proprietary NeXT Platform: Offers comprehensive data analysis for tumor profiling.
- Strategic Partnerships: Collaborations with Mayo Clinic and other institutions enhance research capabilities.
- Advanced Sequencing Technology: Provides accurate and efficient genomic analysis.
- Comprehensive Product Portfolio: Offers a range of solutions for tumor profiling and personalized treatment.
What Does PSNL Do?
Personalis, Inc., founded in 2011 and headquartered in Menlo Park, California, operates as a cancer genomics company. It provides sequencing and data analysis services aimed at supporting the development of cancer therapies and facilitating large-scale genetic research programs. The company's core offering is the NeXT Platform, which delivers comprehensive data analysis of a tumor and its immune microenvironment from limited tissue or plasma samples. This platform is complemented by a suite of products including ImmunoID Next for tumor profiling from tissue, NeXT Liquid Biopsy for tumor profiling from plasma, and NeXT Personal, a liquid biopsy solution for personalized tumor tracking. Personalis also offers NeXT Dx Test, a genomic cancer profiling test designed to enable composite biomarkers for cancer treatment, as well as NeXT SHERPA and NeXT NEOPS for neoantigen prediction. Additionally, the company provides the ACE platform, which supports clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. Personalis serves a diverse clientele, including biopharmaceutical companies, universities, non-profit organizations, and government entities. The company has established partnerships with institutions such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center, enhancing its research and development capabilities and broadening its market reach.
What Products and Services Does PSNL Offer?
- Provides sequencing and data analysis services for cancer therapies.
- Offers the NeXT Platform for tumor and immune microenvironment analysis.
- Provides ImmunoID Next for tumor profiling from tissue samples.
- Offers NeXT Liquid Biopsy for tumor profiling from plasma samples.
- Provides NeXT Personal for personalized tumor tracking.
- Offers NeXT Dx Test for genomic cancer profiling.
- Provides NeXT SHERPA and NeXT NEOPS for neoantigen prediction.
- Offers ACE platform for clinical and therapeutic applications.
How Does PSNL Make Money?
- Provides sequencing and data analysis services to biopharmaceutical companies.
- Generates revenue from sales of its NeXT Platform and related products.
- Partners with universities and research institutions for collaborative projects.
- Offers genomic cancer profiling tests for personalized treatment.
What Industry Does PSNL Operate In?
Personalis, Inc. operates within the rapidly evolving medical diagnostics and research industry, specifically focusing on cancer genomics. The market is characterized by increasing demand for personalized medicine and advanced sequencing technologies. Competitive landscape includes companies like Exact Sciences (EXAS) and Guardant Health (GH), which offer similar diagnostic and genomic profiling services. The industry is driven by technological advancements, increasing investments in cancer research, and a growing emphasis on early detection and targeted therapies. Personalis's NeXT platform positions it to capitalize on these trends by providing comprehensive genomic analysis for cancer treatment and research.
Who Are PSNL's Key Customers?
- Biopharmaceutical companies developing cancer therapies.
- Universities and research institutions conducting genetic research.
- Non-profit organizations focused on cancer research.
- Government entities involved in healthcare and research.
FY2026 estForward Outlook
Wall Street analysts project Personalis, Inc. revenue of about $78.9M for fiscal 2026, with EPS near $-1.03. The estimate reflects 5 contributing analysts.
F-Score 1/9Financial Health
Personalis, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.80 places it in the safe zone, indicating low near-term bankruptcy risk.
PSNL Valuation & Market Position
Relative to its peer group, PSNL's quantitative score of 21/100 is below the peer average of 55/100.
PSNL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying indicates strong confidence in the company's future prospects, suggesting alignment between management and shareholder interests.
- Community sentiment has shifted positively as recent advancements in genomic testing have gained attention, enhancing the company's position in the market.
- Analysts have noted increasing partnerships with healthcare providers, indicating growing trust in their technology and business model.
- The ongoing focus on personalized medicine aligns with broader industry trends, positioning Personalis to capitalize on a growing market.
Bear Case
- Concerns over the competitive landscape have emerged, with several larger firms entering the personalized genomics space, potentially overshadowing Personalis.
- Recent earnings reports have not met market expectations, leading to increased skepticism among investors regarding future growth.
- Social media discussions have highlighted worries about the scalability of their technology, raising questions about long-term operational viability.
- Regulatory uncertainties in the biotech sector could pose risks to business operations, impacting investor confidence in the near term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PSNL Latest News
-
Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks
benzinga · Jul 20, 2026
-
Sector Update: Healthcare Stocks Softer Monday Afternoon
MT Newswires · Jul 20, 2026
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Sep 28, 2023
PSNL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PSNL.
Price Targets
Consensus target: $13.00
PSNL MoonshotScore
What does this score mean?
The MoonshotScore rates PSNL 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Christopher Hall
CEO
Christopher Hall serves as the CEO of Personalis, Inc., bringing extensive experience in the healthcare and biotechnology sectors. Hall has a proven track record of leading and scaling innovative companies. Prior to Personalis, he held key leadership positions at various healthcare firms, focusing on strategic growth and market expansion. His expertise spans genomics, diagnostics, and personalized medicine. Hall's background includes a strong emphasis on driving commercial success and fostering collaborative partnerships within the industry.
Track Record: Since assuming the role of CEO, Christopher Hall has focused on expanding Personalis's NeXT platform and strengthening strategic partnerships. Under his leadership, the company has enhanced its genomic analysis capabilities and broadened its market reach. Hall has also overseen the development of new liquid biopsy solutions and the expansion of the company's customer base. His strategic decisions have aimed at driving long-term growth and improving financial performance.
Personalis, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for PSNL?
PSNL holds an AI Score of 21/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Personalis, Inc. is a cancer genomics company providing sequencing and data analysis services. Their NeXT platform and related products support the development of cancer therapies and large-scale …
What does Personalis, Inc. do?
Personalis, Inc. is a cancer genomics company that provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. The company's core offering is the NeXT Platform, which delivers comprehensive data analysis of a tumor and its immune microenvironment.
What do analysts say about PSNL stock?
Analyst consensus on PSNL stock is mixed, reflecting the company's high-growth potential and financial challenges. Key valuation metrics include market capitalization and revenue growth, with analysts closely monitoring the company's progress in achieving profitability. Growth considerations include the expansion of the NeXT Platform, strategic partnerships, and increased adoption of liquid biopsy solutions.
What are the main risks for PSNL?
The main risks for Personalis, Inc. include intense competition from established diagnostic companies, regulatory hurdles and reimbursement challenges, and technological advancements by competitors. The company's negative profit margin and high beta also pose financial risks. Economic downturns can affect research funding and customer spending, impacting revenue growth.
What are the key factors to evaluate for PSNL?
Personalis, Inc. (PSNL) holds an AI score of 21/100 (low). Analysts target $13.00 (-3%). Not financial advice.
How frequently does PSNL data refresh on this page?
PSNL's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PSNL's recent stock price performance?
Personalis, Inc. (PSNL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Advanced NeXT Platform for comprehensive genomic analysis. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PSNL overvalued or undervalued right now?
Personalis, Inc. (PSNL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $13.00 (-3%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PSNL before investing?
Before investing in Personalis, Inc. (PSNL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be subject to revisions.
- Market projections are based on industry reports and analyst estimates.